These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 28088319)

  • 1. ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt.
    Kassem AB; Salem SE; Abdelrahim ME; Said AS; Salahuddin A; Hussein MM; Bahnassy AA
    Exp Mol Pathol; 2017 Feb; 102(1):78-85. PubMed ID: 28088319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy.
    Huang MY; Tsai HL; Lin CH; Huang CW; Ma CJ; Huang CM; Chai CY; Wang JY
    J Surg Oncol; 2013 Dec; 108(7):457-64. PubMed ID: 23996617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GSTP1, ERCC1 and ERCC2 polymorphisms, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in colorectal cancer in Chinese population.
    Li HY; Ge X; Huang GM; Li KY; Zhao JQ; Yu XM; Bi WS; Wang YL
    Asian Pac J Cancer Prev; 2012; 13(7):3465-9. PubMed ID: 22994779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival.
    Salimzadeh H; Lindskog EB; Gustavsson B; Wettergren Y; Ljungman D
    BMC Cancer; 2020 May; 20(1):409. PubMed ID: 32397974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy.
    Li P; Fang YJ; Li F; Ou QJ; Chen G; Ma G
    Br J Cancer; 2013 Apr; 108(6):1238-44. PubMed ID: 23481186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between ERCC1 and TS mRNA levels and disease free survival in colorectal cancer patients receiving oxaliplatin and fluorouracil (5-FU) adjuvant chemotherapy.
    Li S; Zhu L; Yao L; Xia L; Pan L
    BMC Gastroenterol; 2014 Aug; 14():154. PubMed ID: 25175730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ERCC1 and XPD/ERCC2 polymorphisms' predictive value of oxaliplatin-based chemotherapies in advanced colorectal cancer has an ethnic discrepancy: a meta-analysis.
    Lu X; Xiao S; Jin C; van der Straaten T; Li X
    J Clin Lab Anal; 2012 Jan; 26(1):10-5. PubMed ID: 24833529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis.
    Yin M; Yan J; Martinez-Balibrea E; Graziano F; Lenz HJ; Kim HJ; Robert J; Im SA; Wang WS; Etienne-Grimaldi MC; Wei Q
    Clin Cancer Res; 2011 Mar; 17(6):1632-40. PubMed ID: 21278243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.
    Shirota Y; Stoehlmacher J; Brabender J; Xiong YP; Uetake H; Danenberg KD; Groshen S; Tsao-Wei DD; Danenberg PV; Lenz HJ
    J Clin Oncol; 2001 Dec; 19(23):4298-304. PubMed ID: 11731512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer.
    Stoehlmacher J; Park DJ; Zhang W; Yang D; Groshen S; Zahedy S; Lenz HJ
    Br J Cancer; 2004 Jul; 91(2):344-54. PubMed ID: 15213713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic variability of DNA repair mechanisms influences chemotherapy outcome of gastric cancer.
    Yu H; Wu X; Zhang Y; Jin Z; Li G; Zhao H
    Int J Clin Exp Pathol; 2015; 8(4):4106-12. PubMed ID: 26097599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive Value of ERCC1, ERCC2, and XRCC Expression for Patients with Locally Advanced or Metastatic Gastric Cancer Treated with Neoadjuvant mFOLFOX-4 Chemotherapy.
    Yeh YS; Chen YT; Tsai HL; Huang CW; Ma CJ; Su WC; Huang CM; Huang MY; Hu HM; Lu CY; Wang JY
    Pathol Oncol Res; 2020 Apr; 26(2):1105-1116. PubMed ID: 31077069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.
    Mo J; Luo M; Cui J; Zhou S
    Int J Clin Exp Pathol; 2015; 8(11):15065-71. PubMed ID: 26823845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer.
    Baba H; Watanabe M; Okabe H; Miyamoto Y; Sakamoto Y; Baba Y; Iwatsuki M; Chikamoto A; Beppu T
    Br J Cancer; 2012 Dec; 107(12):1950-5. PubMed ID: 23169295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients.
    Obiedat H; Alrabadi N; Sultan E; Al Shatti M; Zihlif M
    BMC Med Genet; 2018 Jul; 19(1):112. PubMed ID: 29980176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlations between microsatellite instability, ERCC1/XRCC1 polymorphism and clinical characteristics, and FOLFOX adjuvant chemotherapy effect of colorectal cancer patients.
    Zhang L; Zhao J; Yu B; Song X; Sun G; Han L; Wang L; Dong S
    Cancer Genet; 2017 Dec; 218-219():51-57. PubMed ID: 29153096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer.
    Huang ZH; Hua D; Du X; Li LH; Mao Y; Liu ZH; Song MX; Zhou XK
    World J Gastroenterol; 2008 Nov; 14(41):6401-7. PubMed ID: 19009659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics of oxaliplatin as adjuvant treatment in colon carcinoma: are single nucleotide polymorphisms in GSTP1, ERCC1, and ERCC2 good predictive markers?
    Fariña Sarasqueta A; van Lijnschoten G; Lemmens VE; Rutten HJ; van den Brule AJ
    Mol Diagn Ther; 2011 Oct; 15(5):277-83. PubMed ID: 21958378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of ERCC1 expression in peripheral blood lymphocytes with outcomes of patients with gastric cancer treated with oxaliplatin-based adjuvant chemotherapy.
    Zhang YY; Gu KS; Wu HY; Yang F; Bu LJ; Zhao CC; Zhang YR
    Genet Mol Res; 2015 Dec; 14(4):15921-9. PubMed ID: 26662383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic variability of genes in NER pathway influences the treatment outcome of gastric cancer.
    Xue MH; Li GY; Wu XJ; Zhang CX; Zhang CF; Zhu KX
    Int J Clin Exp Pathol; 2015; 8(5):5563-9. PubMed ID: 26191265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.